No one is questioning JAMA publication or the data. But they haven’t been able to use that to bring credible investors on board at a higher floor. Instead they have been selling shares at 60 cents to their friends. And that’s a fact!
JAMA is the most read article (imo) because the NWBO investor community keeps referencing it for more breadcrumbs. I don’t think it is unique views. The data won’t change the more times you look at it. If only views related to stock price.